eTHE (n = 166) | |
---|---|
Tumor localization, n (%) | |
Upper third | 1 (0.6) |
Middle third | 28 (16.9) |
Distal third | 137 (82.5) |
AEG Typ I | 101 (73.7) |
AEG Typ II | 29 (21.2) |
Tumor entity, n (%) | |
Squamous carcinoma, n (%) | 46 (27.7) |
Adenocarcinoma, n (%) | 114 (68.7) |
Others | 6 (3.6) |
(y) pT-Stagea | |
ypT0 | 42 (25.3) |
(y) pT1 | 46 (27.7) |
(y)pT2 | 22 (13.3) |
(y)pT3 | 56 (33.7) |
N-Stagea | |
pN0 | 111 (66.9) |
pN1 | 32 (19.3) |
pN2 | 16 (9.6) |
pN3 | 7 (4.2) |
TNM 8-Stagea | |
I | 89 (53.6) |
II | 19 (11.4) |
IIIA | 15 (9.0) |
IIIB | 30 (18.1) |
IVA | 7 (4.2) |
IVB | 6 (3.6) |
RO resection | 161 (97.0) |
No. of resected lymph nodes | 25 (17.0) |
Complete response (Becker 1a)a | 49 (34.0) |